Last close As at 05/08/2026
—
— 0.00 (0.00%)
Market capitalisation
—
Research: Healthcare
Acacia Pharma has updated the market on the significant ongoing progress of US formulary wins for BARHEMSYS for the treatment and prevention of post-operative nausea and vomiting (PONV) and BYFAVO, an intravenous sedative for use during invasive medical procedures. Formulary access is key for initial sales in the hospital setting and early BARHEMSYS sales should start to trickle through by end FY21/early FY22, while the focus for BYFAVO remains on formulary wins. Obtaining wide formulary adoption is critical and should translate to significant revenue generation from FY22 and maiden operating profit from FY23. Our valuation of Acacia Pharma is unchanged at €1,278m.
Written by
Acacia Pharma |
Progressing on all-important formulary wins |
Commercial update |
Pharma & biotech |
2 July 2021 |
Share price performance
Business description
Next events
Analysts
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||
Acacia Pharma has updated the market on the significant ongoing progress of US formulary wins for BARHEMSYS for the treatment and prevention of post-operative nausea and vomiting (PONV) and BYFAVO, an intravenous sedative for use during invasive medical procedures. Formulary access is key for initial sales in the hospital setting and early BARHEMSYS sales should start to trickle through by end FY21/early FY22, while the focus for BYFAVO remains on formulary wins. Obtaining wide formulary adoption is critical and should translate to significant revenue generation from FY22 and maiden operating profit from FY23. Our valuation of Acacia Pharma is unchanged at €1,278m.
Year end |
Revenue ($m) |
PBT* |
EPS* |
DPS |
P/E |
Yield |
12/19 |
0.0 |
(21.1) |
(0.38) |
0.00 |
N/A |
N/A |
12/20 |
0.2 |
(28.5) |
(0.38) |
0.00 |
N/A |
N/A |
12/21e |
8.0 |
(39.9) |
(0.40) |
0.00 |
N/A |
N/A |
12/22e |
39.7 |
(34.1) |
(0.33) |
0.00 |
N/A |
N/A |
Note: *PBT and EPS are normalised, excluding amortisation of acquired intangibles, exceptional items and share-based payments.
On track to meet FY21 formulary wins
At 30 June 2021 BARHEMSYS (amisulpride injection) was listed on formulary at 201 institutions, significantly ahead of schedule to meet management guidance for 300 by year end and representing a mid-80% win rate. This exceeds original expectations and is particularly impressive given the backdrop of COVID-19. BARHEMSYS use results in shorter times in post-anaesthesia care units, which enables increased surgical throughput. BYFAVO (remimazolam) is now on 47 accounts and management believes it is on track to meet its FY21 target of 150. BYFAVO is the first sedative to be launched in the US in 20 years. Importantly, the broad label granted by the FDA covers all adult invasive medical procedures of less than 30-minute duration (extending utility beyond bronchoscopy and gastroscopy procedures to ophthalmology, interventional radiology and plastic surgery).
FY21 forecasts subject to initial sales pull through
By marketing two products through a small but experienced salesforce, Acacia should realise significant operational synergies. Our peak sales forecasts for BARHEMSYS ($405.3m) and BYFAVO ($125.6m) are unchanged. Our FY21 forecasts are dependent on initial sales pull-through subject to formulary wins and increased physical access to hospitals. We note that further delays to elective procedures are a distinct possibility and present uncertainty. However, the pent-up demand for surgical procedures and sedative drug shortages in the United States could lead to early sales uptake of both products.
Valuation: €1,278m or €12.8/share
Our unchanged valuation is €1,278m or €12.8/share. Acacia is funded into 2022 and we model additional funding of c $35m will be needed in H222 for further commercial expansion. Given Acacia’s operational focus on the United States and the opportunities for BARHEMSYS and BYFAVO in this key market, we believe a Nasdaq listing would be appropriate to further widen the investor base.
Exhibit 1: Financial summary
Year end 31 December (US$m) |
|
|
2018 |
2019 |
2020 |
2021e |
2022e |
PROFIT & LOSS |
|
|
|
|
|
|
|
Operating revenues |
|
|
0.0 |
0.0 |
0.2 |
8.0 |
39.7 |
Cost of sales |
|
|
0.0 |
0.0 |
(0.0) |
(0.5) |
(3.1) |
Gross profit |
|
|
0.0 |
0.0 |
0.2 |
7.5 |
36.6 |
Gross margin % |
|
|
N/A |
N/A |
86% |
94% |
92% |
SG&A (expenses) |
|
|
(15.0) |
(18.5) |
(31.0) |
(50.6) |
(68.9) |
R&D costs |
|
|
(5.0) |
(3.9) |
(0.1) |
(1.0) |
(7.0) |
Other income/(expense) |
|
|
0.0 |
0.0 |
0.0 |
0.0 |
0.0 |
EBITDA |
|
|
(20.0) |
(22.3) |
(27.8) |
(36.0) |
(31.2) |
Reported operating Income |
|
|
(20.0) |
(22.4) |
(30.9) |
(44.1) |
(39.3) |
Operating Margin % |
|
|
N/A |
N/A |
N/A |
N/A |
N/A |
Finance income/(expense) |
|
|
(1.5) |
(1.1) |
(3.2) |
(3.9) |
(2.8) |
Exceptionals and adjustments |
|
|
0.0 |
0.0 |
0.0 |
0.0 |
0.0 |
Reported profit before tax |
|
|
(21.6) |
(23.5) |
(34.1) |
(48.0) |
(42.1) |
Normalised profit before tax |
|
|
(20.9) |
(21.1) |
(28.5) |
(39.9) |
(34.1) |
Income tax expense (includes exceptionals) |
|
|
0.9 |
0.7 |
0.6 |
0.7 |
0.7 |
Reported net income |
|
|
(20.7) |
(22.8) |
(33.5) |
(47.3) |
(41.4) |
Basic average number of shares, m |
|
|
44.1 |
53.7 |
73.6 |
98.1 |
99.7 |
Year-end number of shares, m |
|
|
53.3 |
54.9 |
89.6 |
99.7 |
99.7 |
Basic EPS ($) |
|
|
(0.47) |
(0.43) |
(0.45) |
(0.48) |
(0.42) |
Adjusted EPS ($) |
|
|
(0.45) |
(0.38) |
(0.38) |
(0.40) |
(0.33) |
Dividend per share ($) |
|
|
0.00 |
0.00 |
0.00 |
0.00 |
0.00 |
|
|
|
|
|
|
|
|
BALANCE SHEET |
|
|
|
|
|
|
|
Property, plant and equipment |
|
|
0.0 |
0.0 |
0.0 |
0.3 |
2.2 |
Intangible assets |
|
|
0.0 |
0.0 |
52.2 |
44.1 |
36.1 |
Other non-current assets |
|
|
0.0 |
0.4 |
0.3 |
0.3 |
0.3 |
Total non-current assets |
|
|
0.0 |
0.4 |
52.4 |
44.8 |
38.6 |
Cash and equivalents |
|
|
37.4 |
17.0 |
46.7 |
35.0 |
31.0 |
Inventories |
|
|
0.0 |
0.0 |
2.7 |
1.0 |
4.3 |
Trade and other receivables |
|
|
0.4 |
0.6 |
0.5 |
1.4 |
4.3 |
Other current assets |
|
|
0.9 |
0.7 |
0.6 |
0.6 |
0.6 |
Total current assets |
|
|
38.7 |
18.3 |
50.4 |
38.0 |
40.2 |
Non-current loans and borrowings |
|
|
8.9 |
4.7 |
31.3 |
31.3 |
66.3 |
Other non-current liabilities |
|
|
0.0 |
0.0 |
0.0 |
0.0 |
0.0 |
Total non-current liabilities |
|
|
8.9 |
4.7 |
31.3 |
31.3 |
66.3 |
Trade and other payables |
|
|
4.7 |
4.2 |
5.7 |
6.9 |
9.4 |
Current loans and borrowings |
|
|
0.5 |
5.5 |
5.4 |
0.0 |
0.0 |
Other current liabilities |
|
|
0.0 |
0.0 |
0.0 |
0.0 |
0.0 |
Total current liabilities |
|
|
5.2 |
9.6 |
11.1 |
6.9 |
9.4 |
Equity attributable to company |
|
|
24.7 |
4.3 |
60.5 |
44.5 |
3.1 |
|
|
|
|
|
|
|
|
CASH FLOW STATEMENT |
|
|
|
|
|
|
|
Profit before tax |
|
|
(21.6) |
(23.5) |
(34.0) |
(48.0) |
(42.1) |
Depreciation and amortisation |
|
|
0.0 |
0.1 |
3.1 |
8.1 |
8.1 |
Share based payments |
|
|
0.6 |
2.4 |
2.6 |
0.0 |
0.0 |
Other adjustments |
|
|
1.5 |
1.1 |
3.2 |
3.9 |
2.8 |
Movements in working capital |
|
|
(3.9) |
(0.8) |
(1.0) |
2.0 |
(3.7) |
Interest paid |
|
|
0.0 |
0.0 |
0.0 |
(3.9) |
(2.8) |
Income taxes paid |
|
|
0.4 |
0.8 |
0.7 |
0.7 |
0.7 |
Cash from operations (CFO) |
|
|
(15.4) |
(19.8) |
(25.4) |
(37.3) |
(37.1) |
Capex |
|
|
0.0 |
0.0 |
0.0 |
(0.4) |
(1.9) |
Acquisitions & disposals net |
|
|
0.0 |
0.0 |
0.0 |
0.0 |
0.0 |
Other investing activities |
|
|
0.2 |
0.4 |
0.0 |
0.0 |
0.0 |
Cash used in investing activities (CFIA) |
|
|
0.2 |
0.4 |
0.0 |
(0.3) |
(1.9) |
Net proceeds from issue of shares |
|
|
47.1 |
0.2 |
48.4 |
31.4 |
0.0 |
Movements in debt |
|
|
1.8 |
(1.0) |
7.7 |
(5.4) |
35.0 |
Other financing activities |
|
|
0.0 |
(0.1) |
(0.1) |
0.0 |
0.0 |
Cash from financing activities (CFF) |
|
|
48.9 |
(0.9) |
56.0 |
25.9 |
35.0 |
Cash and equivalents at beginning of period |
|
|
4.1 |
37.4 |
17.0 |
46.7 |
35.0 |
Increase/(decrease) in cash and equivalents |
|
|
33.7 |
(20.3) |
30.7 |
(11.7) |
(3.9) |
Effect of FX on cash and equivalents |
|
|
(0.4) |
(0.1) |
(1.0) |
0.0 |
0.0 |
Cash and equivalents at end of period |
|
|
37.4 |
17.0 |
46.7 |
35.0 |
31.0 |
Net (debt)/cash |
|
|
28.1 |
6.9 |
10.0 |
3.7 |
(35.3) |
Source: Acacia Pharma, Edison Investment Research
|
|
Research: Real Estate
While publity continues to pursue its two-pillar strategy based on real estate asset management and own investments, it is in discussions with a large Asian conglomerate to sell a majority stake in PREOS, which (through publity Investor and GORE German Office Real Estate) holds the group’s investment properties. The parties are also negotiating the provision of an additional three-digit million euro in funding to PREOS (on the successful closure of the deal) to fuel its international portfolio expansion. Meanwhile, the FY20 results of the asset management business were below FY19 due to the impact of the pandemic on property transaction volumes.